During blood cancer awareness month in September, many companies and organisations used the opportunity to bring awareness to the multiple therapy areas and indications under the blood cancer umbrella, including acute myeloid leukaemia (AML).

AML is a type of cancer that results in excess immature white and red blood cells and platelets. An analysis of the current clinical trial space for AML can be completed in the Clinical Trials Database of GlobalData’s Pharma Intelligence Center.

In this article, a small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Looking at all of the AML clinical trials in the database, most trials (56.7%) are in Phase II, as seen in Figure 1. Additionally, 26.4% are in Phase I, 11.8% are in Phase III, and 5.2% are in Phase IV. Based on trial status, most trials were currently ongoing (82.3%). This was followed by completed (53.4%); suspended, terminated, and withdrawn (S/T/W) (15.0%); and planned (6.1%) (Figure 2).

While using the Feasibility Planner of the Clinical Trials Database, obstacles can be identified and analyzed to avoid trials becoming S/T/W. As seen in Figure 3, the top five obstacles include low accrual rate, adverse events, lack of efficacy, financial, and business/strategic decisions. Low accrual rate is the only obstacle seen in all four phases.